Semax for Sale USA: What Customs Risk Adds to $3.00/mg

Domestic dispatch changes four numbers, and only one of them is the price on the listing.

Two of those rows are honest about not knowing. Nobody publishes a seizure rate for research peptide parcels, and any page that gives you one as a fact has made it up. What can be done is the sensitivity analysis: assume nothing about the rate, and show what the answer looks like across a range of them, so you can substitute whatever number your own experience supports.

The domestic side of the table is the part that is checkable. Same-day dispatch before 2pm CST, free carriage over $250, and a batch number on the vial that matches a published certificate. Those are claims you can test on a single order rather than beliefs you have to hold.

The mechanism is one line of arithmetic. If a fraction of parcels never arrives, the effective cost per milligram received is the sticker divided by the fraction that does. Below, a hypothetical overseas listing at $2.40 a milligram, which is 20 percent under the domestic figure, run across a range of loss rates. None of these rates is a measurement. They are there so you can find the row you believe.

The break-even is the row worth memorising. A 20 percent discount on the sticker is entirely consumed by a one-in-five loss rate, and a listing has to be very substantially cheaper before it survives a rate any higher than that. This is why cross-border price advantages on research peptides tend to be smaller than they look, and it is arithmetic rather than an opinion about any particular seller.

Three costs are not even in the table. The weeks between a stopped parcel and a replacement, which the model treats as free and which are not. Any duty or handling fee a carrier applies, which divides by ten milligrams rather than scaling with them. And the certificate question, because a parcel that arrives with no batch number to match is a purchase you cannot verify at any price. Our page on buying retatrutide across a border runs the same structure against a jurisdiction with a published tax rate, where at least one of the unknowns becomes a number.

Any listing can say it ships from the USA. Three things make the claim checkable rather than decorative, and all three are on the vial or the paperwork rather than in the marketing copy.

• A batch number that matches a published certificate. The vial should carry a batch code, and that code should appear on a certificate you can open without asking anyone. Two are published for this listing and they do not cover the same ground: the February one, from MZ Biolabs on lot 30-01260229, stops at purity, quantity and identity, while batch 30-05260628 is a four-part Kovera Labs report numbered KVR-2026-E848E0 that adds endotoxin, sterility and heavy metals. Which one applies to you is decided by the code on your vial, not by the compound.
• A report identifier you can take to the laboratory. The certificate carries the issuing laboratory's own verification address and per-section access codes, which means the document is checkable at source rather than only readable as a PDF a seller handed you. That is a meaningfully higher bar than a scanned image with a logo on it.
• A domestic return address and a stated refund policy. The point of buying domestically is that something can be sent back. A seller who ships from a US warehouse but routes returns overseas has given you the shipping speed without the recourse, which is the half of domestic supply that actually costs them money.

One inconsistency in the paperwork is worth knowing about, because a careful reader will find it and should not be alarmed by it. The endotoxin section headers describe a kinetic chromogenic LAL assay, and one row inside the same table labels the assay type as kinetic turbidimetric. Both are recognised methods under the same compendial chapter. It reads as a template artefact rather than a result problem, the reported figure and acceptance limit are unaffected, and it is exactly the sort of thing to raise with a seller if you want to see how they answer a specific question.

What none of this verifies is the compound's standing, which is the next section, or the safety of using it, which nothing on a certificate can establish.

The reason there is no pharmacy shelf to compare against is regulatory, and the precise history is worth getting right because most pages garble it.

Semax was nominated for the section 503A bulks list. It was placed in category 2 under FDA's interim policies while the agency evaluated it, and the nomination was then withdrawn by the nominator. Today it appears on FDA's list of bulk drug substances nominated but withdrawn, and it is in none of the three categories on the current 503A lists, which were last updated on 14 May 2026. It has no FDA approval for any indication. If you have read that Semax is currently an FDA category 2 substance, that is a stale fact rather than a false one; it was, and it is not now.

FDA's recorded concern is worth quoting once because it explains what testing to look for. Compounded drugs containing semax (heptapeptide) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.

The practical consequence for a US buyer is that the compounding pharmacy channel is closed, so the domestic supply that does exist is research material sold as research material. That is also why the endotoxin and sterility lines on this batch certificate carry weight: aggregation and impurities are measurable, and this certificate measures a larger share of them than most. It does not make the compound safe, and a clean result on one batch is evidence about one batch. Our page on the legal position works through the whole of it, and Selank sits in the same position for the same reasons, covered on the Selank domestic supply page.

Domestic transit shortens the window in which anything can go wrong, and the material is comparatively forgiving in the state it ships in. The certificate records the condition tested as lyophilised powder, and a dry sealed vial is the most robust form this compound comes in. The fragile phase starts when you add water, which happens after delivery and under your control rather than a carrier's. Our peptide storage guide is the right place for handling temperatures; what belongs here is the buying consequence.

Price a failure in milligrams rather than dollars, because dollars understate it. A vial lost, spoiled or refused is not a $30.00 event. It is a 10 mg event, which is 200 units of a 2 mL preparation, or 11.23 mg if your batch is the one that was weighed. At $3.00 a labelled milligram that is $30.00 of material plus whatever the wait costs, and the wait is where domestic and overseas actually separate.

The first row is the one that recurs. Hold-up volume in the shoulder and the needle hub is unrecoverable and it is roughly 2.5 percent of a 2 mL preparation, moving the effective rate from $3.00 to $3.08 a milligram every single time. That is a permanent 8 cent tax on every milligram, larger than most of the differences people change vendors over, and no discount code or shipping arrangement touches it.

On freight, the arithmetic runs the wrong way for a single vial. Free carriage starts at $250, so five vials at list is $299.95 and clears it while the same five vials halved by the code would be $150.00 and would not. Whichever route you take, shipping divides by the milligrams in the box rather than scaling with them, which is the one respect in which buying more genuinely is cheaper per milligram.